ADA Scientific Sessions 2021
June 25-29, 2021
ADA’s Virtual 81st Scientific Sessions features discussion from leading diabetes experts on topics ranging from diabetes technology to advances in prevention and patient care. Included is 800 presentations, more than 1,000 poster presentations, and an online poster forum. Registration is required to view presentations. For more information, please visit: professional.diabetes.org.
Carelon Research presentations
Carelon Research authors are indicated in bold.
|
Presentation |
Title |
Authors |
Affiliations |
|---|---|---|---|
|
General poster session Friday, June 25, 2020 |
649-P | Impact of early initiation of dulaglutide on A1C in patients with type 2 diabetes |
Hoog M1, Smith J2, Yu M1, Peleshok J1, Mody R1, Grabner M2 |
1Eli Lilly and Company, Indianapolis, IN, 2Carelon Research, Wilmington, DE |
|
General poster session Friday, June 25, 2020 |
652-P | Real-world effectiveness of once-weekly semaglutide (sema OW) from a US commercially insured and Medicare advantage population |
Willey V1, Shivappa N1, Noone J2, Swift C2, Du S1, Paprocki YM2, Tan H1 |
1Carelon Research, Wilmington, DE, 2Novo Nordisk, Plainsboro Township, NJ |
|
General poster session Friday, June 25, 2020 |
653-P | Evaluating antidiabetic medication treatment patterns in T2D patients initiating once-weekly semaglutide (sema OW) |
Willey V1, Shivappa N1, Swift C2, Noone J2, Du S1, Paprocki YM2, Tan H1 |
1Carelon Research, Wilmington, DE, 2Novo Nordisk, Plainsboro Township, NJ |
|
General poster session Friday, June 25, 2020 |
683-P | Real-world evaluation of once-weekly semaglutide (sema OW) in patients newly initiating GLP-1 agonist therapy |
Shivappa N1, Swift C2, Noone J2, Du S1, Paprocki YM2, Tan H1, Willey V1 |
1Carelon Research, Wilmington, DE, 2Novo Nordisk, Plainsboro Township, NJ |
|
General poster session Friday, June 25, 2020 |
805-P | Risk of severe complications of urinary tract infection in real-world use of dapagliflozin |
Johannes C1, Layton J1, Beachler DC2, Ziemiecki RM1, Li L2, Danysh HE1, Dinh J2, Hunt PR3, Karlsson C3, Chen H3, Gilsenan A1 |
1RTI, Research Triangle Park, NC, 2Carelon Research, Wilmington, DE, 3AstraZeneca, Gaithersburg, MD |
|
General poster session Friday, June 25, 2020 |
806-P | Risk of acute liver injury in real-world use of dapagliflozin |
Johannes C1, Chen H3, Gilsenan A1, Layton J1, Beachler DC2, Ziemiecki RM1, Li L2, Danysh HE1, Dinh J2, Hunt PR3, Karlsson C3 |
1RTI, Research Triangle Park, NC, 2Carelon Research, Wilmington, DE, 3AstraZeneca, Gaithersburg, MD |
|
General poster session Friday, June 25, 2020 |
1271-P | Real-World effectiveness of newly initiated once-weekly semaglutide (sema OW) by prescriber specialty |
Shivappa N1, Noone J2, Swift C2, Du S1, Tan H1, Paprocki YM2, Willey V1 |
1Carelon Research, Wilmington, DE, 2Novo Nordisk, Plainsboro Township, NJ |
|
Late breaking poster session Friday, June 25, 2020 |
50-LB | Using cluster analysis to identify attitudes towards diabetes-related technology |
Eby EL1, Stephenson JJ2, Gelsey F1, Poon J1, Governor SB2, Nguyen C2, Willey V2 |
1Eli Lilly and Company, Indianapolis, IN, 2Carelon Research, Wilmington, DE |
|
Late breaking poster session Friday, June 25, 2020 |
86-LB | Real-world effectiveness of oral semaglutide (OS) from a US commercially insured and Medicare advantage population |
Shivappa N1, Swift C2, Noone J2, Du S1, Radin M2, Gamble C2, Tan H1, Willey V1 |
1Carelon Research, Wilmington, DE, 2Novo Nordisk, Plainsboro Township, NJ |
|
Oral presentation Friday, June 25, 2020 |
14-OR | Risk of acute kidney injury in real-world use of dapagliflozin |
Johannes C1, Layton J1, Beachler DC2, Ziemiecki RM1, Li L2, Danysh HE1, Dinh J2, Hunt PR3, Karlsson C3, Chen H3, Gilsenan A1 |
1RTI, Research Triangle Park, NC, 2Carelon Research, Wilmington, DE, 3AstraZeneca, Gaithersburg, MD |
